Genmab Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Copenhagen V, Denmark
Total Funding:$134M
Industry:Biotech
Founded:1999
Lead Investor(s):Janssen Biotech Inc

Industry Ranking

Estimated Revenue & Financials

  • Genmab's estimated annual revenue is currently $98.4M per year.
  • Genmab received $10.0M in venture funding in October 2014.
  • Genmab's estimated revenue per employee is $155,000
  • Genmab's total funding is $134M.

Employee Data

  • Genmab has 635 Employees.
  • Genmab grew their employee count by 37% last year.
  • Genmab currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Genmab
$98.4M63537%N/AN/A
Gubra
$27.7M17934%N/AN/A
Unibio
$8.4M548%N/AN/A
Orphazyme
$24.8M16045%N/AN/A
Ascendis Pharma...
$63.1M40745%N/AN/A
Missing a competitor? Contribute!?
Submit

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimer

keywords:N/A

635

Number of Employees

$98.4M

Revenue (est)

1

Current Jobs

37%

Employee Growth %

$134M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Annette Ervin-HaynesVice PresidentEmail Available
Carl SharoAssociate Director of Facilities
Jan van de WinkelCEO/PresidentEmail Available
David EatwellExecutive Vice President & Chief Financial OfficerEmail Available
Birgitte StephensenSVP Legal/IPREmail Available
Anthony PaganoSvp Global Finance & Corporate DevelopmentEmail Available
Rachel GravesenSenior Vice President, Investor Relations and Communications
Dena DemarcoSr. Director, Clinical Research Scientist
Maryanne MccarthySr. Director Alliance Management
Martine van VugtSVP Strategic InitiativesEmail Available

Genmab News

09/03/2019 - Genmab and Tempus Enter into Strategic Collaboration ...

Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned ...

09/08/2019 - Tempus, Genmab Enter Oncology Biomarker Collaboration

Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that ...

09/03/2019 - Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement. Copenhagen, Denmark; August 20, 2019 – Genmab A/S (Nasdaq:GMAB) will increase its share capital by 21,811 ...

Genmab Funding

DateAmountRoundLead InvestorsReference
2014-10-27$10.0MUndisclosedJanssen Biotech IncArticle

Genmab Executive Hires

DateNameTitleReference
2017-02-10Judith KlimovskyChief Development OfficerArticle